A global pandemic influenza vaccine action plan

Kiény, Marie Paule; Costa, Alejandro; Hombach, Joachim; Carrasco, Peter; Pervikov, Yuri; Salisbury, David; Gréco, Michel; Gust, Ian D.; LaForce, Marc; Franco‐Paredes, Carlos; Santos, José Ignacio; D'Hondt, E.; Rimmelzwaan, Guus F.; Karron, Ruth A.; Fukuda, Keiji

doi:10.1016/j.vaccine.2006.07.021

Cited by 81 publications

(66 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is probably most relevant for pandemic influenza vaccines where global production capacity limits access to a vaccine at the start of a pandemic. 3 In 2009, H1N1 vaccine was not available in most low-income countries until 8 months after WHO's declaration of the influenza pandemic. 4 Other vaccines with potential supply constraints include yellow fever and inactivated poliovirus vaccines.…”

Section: Potential Benefitsmentioning

confidence: 99%

Intradermal delivery of vaccines: potential benefits and current challenges

Hickling¹,

Jones²,

Friede

et al. 2011

Bull. World Health Organ.

165

137

View full text Add to dashboard Cite

Section: Potential Benefitsmentioning

confidence: 99%

Intradermal delivery of vaccines: potential benefits and current challenges

Hickling¹,

Jones²,

Friede

et al. 2011

Bull. World Health Organ.

165

137

View full text Add to dashboard Cite

“…For the inactivated trivalent influenza vaccine (hereinafter referred to as TIV), each 0.5-ml dose of TIV contains 15 g of influenza HA of each strain (45 g total) from three viral strains: two influenza A virus subtypes (H1N1 and H3N2) and one influenza B virus strain. The seasonal inactivated TIV is the most commonly administered influenza vaccine, and each year hundreds of millions of individuals are vaccinated worldwide (20,21).…”

mentioning

confidence: 99%

Seasonal Trivalent Inactivated Influenza Vaccine Protects against 1918 Spanish Influenza Virus Infection in Ferrets

Pearce

Belser

Gustin

et al. 2012

J Virol

View full text Add to dashboard Cite

“…A summary of the meeting reports that an investment of US$3-10 billion might begin to bear fruit in three to five years (Kieny et al 2006). Not considered by the World Health Organization, but another means of boosting effective supply, would be harmonization of regulatory standards among countries (Gronvall and Borio 2006).…”

Section: Policy Responses To Pandemic Influenzamentioning

confidence: 99%

Pandemic Influenza: A Review

MacKellar

2007

Population & Development Rev

View full text Add to dashboard Cite

This essay, written ten years after the first human death from avian influenza, reviews scientific, social, and policy aspects of pandemic influenza, and asks whether the near‐crisis level of concern is justified. That there will be another influenza pandemic is certain, and a number of factors suggest it will occur sooner rather than later. It is impossible, however, to predict two of the pandemic's crucial characteristics—its pathogenicity and the age‐attack curve. The scientific arsenal has never been stronger, yet gaps in the availability of antiviral drugs and vaccines are inevitable, and the world is poorly prepared to cope with the politics of drug shortage. Some studies suggest emergent pandemics can be “ring‐fenced,” but these studies are not broadly accepted. Assuming that they cannot, rapid and global deployment of a range of responses, including social distancing, travel limitations, and prophylactic/curative application of antiviral drugs such as Tamiflu, can limit impacts. However, the impacts are bound to be significant if not severe. Overall health‐sector strengthening, rural development (particularly in the area of veterinary health), and addressing the local, national, and international governance issues that cut across all aspects of infectious disease are more likely to bear fruit, especially in the developing world, than the pandemic preparedness planning now in vogue.

show abstract

A global pandemic influenza vaccine action plan

Cited by 81 publications

References 0 publications

Intradermal delivery of vaccines: potential benefits and current challenges

Intradermal delivery of vaccines: potential benefits and current challenges

Seasonal Trivalent Inactivated Influenza Vaccine Protects against 1918 Spanish Influenza Virus Infection in Ferrets

Pandemic Influenza: A Review

Contact Info

Product

Resources

About